Resultados da pesquisa - Xuhui Bao

  • A mostrar 1 - 12 resultados de 12
Refinar resultados
  1. 1
    Targeting purinergic pathway to enhance radiotherapy-induced immunogenic cancer cell death

    Targeting purinergic pathway to enhance radiotherapy-induced immunogenic cancer cell death Por Xuhui Bao, Liyi Xie

    Publicado em 2022
    Obter o texto integral Obter o texto integral
    Revisão
    Adic. favoritos
    Na minha lista:
  2. 2
    SETDB1 Restrains Endogenous Retrovirus Expression and Antitumor Immunity during Radiotherapy

    SETDB1 Restrains Endogenous Retrovirus Expression and Antitumor Immunity during Radiotherapy Por Dong Pan, Xuhui Bao, Mengjie Hu, Meng Jiao, Fang Li, Chuan‐Yuan Li

    Publicado em 2022
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  3. 3
    Endogenous Retrovirus Activation as a Key Mechanism of Anti-Tumor Immune Response in Radiotherapy

    Endogenous Retrovirus Activation as a Key Mechanism of Anti-Tumor Immune Response in Radiotherapy Por Andrew K. Lee, Dong Pan, Xuhui Bao, Mengjie Hu, Fang Li, Chuan‐Yuan Li

    Publicado em 2020
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  4. 4
    ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS/STING activation

    ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS/STING activation Por Mengjie Hu, Min Zhou, Xuhui Bao, Dong Pan, Meng Jiao, Xinjian Liu, Fang Li, Chuan‐Yuan Li

    Publicado em 2020
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  5. 5
    Bacterial‐Mediated Tumor Therapy: Old Treatment in a New Context

    Bacterial‐Mediated Tumor Therapy: Old Treatment in a New Context Por Yao Liu, Lili Niu, Nannan Li, Yang Wang, Mingyang Liu, Xiaomin Su, Xuhui Bao, Bo Yin, Shun Shen

    Publicado em 2023
    Obter o texto integral Obter o texto integral
    Revisão
    Adic. favoritos
    Na minha lista:
  6. 6
    Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside

    Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside Por Xuhui Bao, Yongjun Liang, Hanman Chang, Tianji Cai, Baijie Feng, Константин Гордон, Yuekun Zhu, Hailian Shi, Yundong He, Liyi Xie

    Publicado em 2024
    Obter o texto integral Obter o texto integral
    Revisão
    Adic. favoritos
    Na minha lista:
  7. 7
    Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer

    Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer Por Xinjian Liu, Xuhui Bao, Mengjie Hu, Hanman Chang, Meng Jiao, Jin Cheng, Liyi Xie, Qian Huang, Fang Li, Chuan‐Yuan Li

    Publicado em 2020
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  8. 8
    Recombinant anti‐podoplanin (NZ‐1) immunotoxin for the treatment of malignant brain tumors

    Recombinant anti‐podoplanin (NZ‐1) immunotoxin for the treatment of malignant brain tumors Por Vidyalakshmi Chandramohan, Xuhui Bao, Mika K. Kaneko, Yukinari Kato, Stephen T. Keir, Scott E. Szafranski, Chien‐Tsun Kuan, Ira Pastan, Darell D. Bigner

    Publicado em 2012
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  9. 9
    Construction of an Immunotoxin, D2C7-(scdsFv)-PE38KDEL, Targeting EGFRwt and EGFRvIII for Brain Tumor Therapy

    Construction of an Immunotoxin, D2C7-(scdsFv)-PE38KDEL, Targeting EGFRwt and EGFRvIII for Brain Tumor Therapy Por Vidyalakshmi Chandramohan, Xuhui Bao, Stephen T. Keir, Charles N. Pegram, Scott E. Szafranski, Hailan Piao, Carol J. Wikstrand, Roger E. McLendon, Chien‐Tsun Kuan, Ira Pastan, Darell D. Bigner

    Publicado em 2013
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  10. 10
    Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations

    Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations Por Vidya Chandramohan, Xuhui Bao, Xin Yu, Scott Parker, Charlotte McDowall, Yen-Rei Andrea Yu, Patrick Healy, Annick Desjardins, Michael D. Gunn, Matthias Gromeier, Smita K. Nair, Ira Pastan, Darell D. Bigner

    Publicado em 2019
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  11. 11
    XIAP Regulation by MNK Links MAPK and NFκB Signaling to Determine an Aggressive Breast Cancer Phenotype

    XIAP Regulation by MNK Links MAPK and NFκB Signaling to Determine an Aggressive Breast Cancer Phenotype Por Myron K. Evans, Michael C. Brown, Joseph Geradts, Xuhui Bao, Timothy J. Robinson, Mohit Kumar Jolly, Peter Vermeulen, Gregory M. Palmer, Matthias Gromeier, Herbert Levine, Michael A. Morse, Steven Van Laere, Gayathri R. Devi

    Publicado em 2018
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  12. 12
    KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation

    KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation Por Changcun Guo, Lee H. Chen, Yafen Huang, Chun‐Chi Chang, Ping Wang, Christopher J. Pirozzi, Xiaoxia Qin, Xuhui Bao, Paula K. Greer, Roger E. McLendon, Hai Yan, Stephen T. Keir, Darell D. Bigner, Yiping He

    Publicado em 2013
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:

Ferramentas de pesquisa: